According to the NCI website, oprelvekin is a recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin 11 (IL-11).

IIndikationen/Anwendungsmöglichkeiten gemäss Chemocare.com:
Oprelvekin is used to stimulate the bone marrow to produce platelets in order to prevent low platelets that may be caused by chemotherapy. Platelets are blood cells that allow the blood to clot, and prevent bleeding.
Oprelvekin may be given to decrease the need for platelet transfusions.
Oprelvekin is not indicated for myeloid malignancies (diseases that start in the bone marrow such as leukemia).
Oprelvekin is a support medication. It does not treat cancer.

Link to Drug Information Portal
Link to MedlinePlus
Link to National Cancer Institute
Link zu Wiki
Link to Physicians Desk Reference (PDR)
Info for Patients presented by Scott Hamilton from Chemocare.com